keyword
MENU ▼
Read by QxMD icon Read
search

Vaginal atrophy

keyword
https://www.readbyqxmd.com/read/29140150/radiotherapy-for-cervical-cancer-impact-on-the-vaginal-epithelium-and-sexual-function
#1
Alexandra Hofsjö, Karin Bergmark, Bo Blomgren, Helen Jahren, Nina Bohm-Starke
BACKGROUND: Women who have been treated for cervical cancer have persistent changes in their sexual function, which result in considerable distress. The aim of this study was to investigate the morphology of the vaginal epithelium in cervical cancer survivors treated with radiotherapy and its correlation to serum levels of sex steroid hormones and sexual function. MATERIAL AND METHODS: We included 34 patients treated for cervical cancer with radiotherapy and 37 healthy age-matched control women scheduled for benign gynecological surgery...
November 15, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29104812/evaluation-of-the-co2-laser-therapy-on-vulvo-vaginal-atrophy-vva-in-oncological-patients-preliminary-results
#2
Isabella Pagano, Stefania Gieri, Francesca Nocera, Giuseppe Scibilia, Filippo Fraggetta, Antonio Galia, Mauro Gioè, Basilio Pecorino, Paolo Scollo
Objective: To evaluate the impact of fractionated CO2 laser therapy on vaginal atrophy and mild/moderate stress urinary incontinence (SUI) symptoms in patients with physiological or surgically-induced menopause. Materials and Methods: Post-menopausal patients (n = 33) presenting vaginal atrophy and/or SUI, underwent three vaginal CO2 laser treatment sessions, performed at 1-month intervals. Vaginal symptoms were evaluated using the Vaginal Health Index Score (VHI-S), Visual Analogue Scales (VAS) for dyspareunia and global patient satisfaction...
May 2017: Journal of Cancer Therapy
https://www.readbyqxmd.com/read/29064335/overall-safety-of-ospemifene-in-postmenopausal-women-from-placebo-controlled-phase-2-and-3-trials
#3
James A Simon, Corrado Altomare, Susannah Cort, Wei Jiang, JoAnn V Pinkerton
OBJECTIVE: To evaluate the safety of daily oral ospemifene 60 mg, estrogen agonist/antagonist, used to treat moderate-to-severe dyspareunia due to postmenopausal vulvovaginal atrophy, which is part of genitourinary syndrome of menopause. METHODS: Post hoc analysis of safety data (treatment-emergent adverse events [TEAEs]) pooled from six phase 2 and 3 randomized, double-blind, multicenter placebo-controlled studies, evaluating the effects of ospemifene 60 mg on the breast, cardiovascular system, and bone in postmenopausal women...
October 24, 2017: Journal of Women's Health
https://www.readbyqxmd.com/read/29061288/co2-laser-treatment-is-effective-for-symptoms-of-vaginal-atrophy-no
#4
Ekene A Enemchukwu
No abstract text is available yet for this article.
December 2017: Journal of Urology
https://www.readbyqxmd.com/read/29061287/co2-laser-treatment-is-effective-for-symptoms-of-vaginal-atrophy
#5
Jennifer T Anger
No abstract text is available yet for this article.
December 2017: Journal of Urology
https://www.readbyqxmd.com/read/29057583/a-medical-device-containing-purified-bovine-colostrum-monurelle-biogel-in-the-treatment-of-vulvovaginal-atrophy-in-postmenopausal-women-retrospective-analysis-of-urinary-symptoms-sexual-function-and-quality-of-life
#6
M C Schiavi, C Di Tucci, V Colagiovanni, P Faiano, A Giannini, O D'Oria, G Prata, G Perniola, M Monti, M A Zullo, L Muzii, P Benedetti Panici
OBJECTIVE: This study assessed the effectiveness and safety of a medical device containing purified bovine colostrum (Monurelle Biogel; Zambon, Bresso, Italy) in improving vulvovaginal atrophy (VVA), sexual function, urinary symptoms, and quality of life (QoL) in postmenopausal women. METHODS: In all, 172 postmenopausal women with VVA were included in the study. All women were treated with vaginal Monurelle Biogel daily for 12 weeks. Patients underwent clinical examinations, completed a 3-day voiding diary, and had VVA graded using the Vaginal Health Index (VHI) at baseline and 12 weeks...
October 23, 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/29044352/-sulphurous-vaginal-douching-and-vulvovaginal-atrophy
#7
M Costantino, V Conti, M B Marongiu, G Napolano, A Filippelli
OBJECTIVE: During climacteric the reduction or interruption of estrogenic stimulus determines a gradual atrophy of the tissues of the urogenital tract.Vulvovaginal atrophy can be cause of dryness, itch, burning, and dyspareunia. Vulvovaginal atrophy is associated also with depression. Hence the importance of an appropriate treatment of the vulvovaginal atrophy. Between therapeutic options we can add, particularly for women who suffer only from vaginal symptoms, the spa therapy that uses mineral waters with benefic effects on vaginal tissue wellness and health...
September 2017: La Clinica Terapeutica
https://www.readbyqxmd.com/read/29040373/nonsurgical-vulvovaginal-rejuvenation-with-radiofrequency-and-laser-devices-a-literature-review-and-comprehensive-update-for-aesthetic-surgeons
#8
Ali A Qureshi, Marissa M Tenenbaum, Terence M Myckatyn
Nonsurgical vulvovaginal rejuvenation (NVR) is growing in popularity as a treatment for restoration of youthful female genitalia. Numerous radiofrequency (RF) and laser devices have entered the market claiming improvement in vaginal laxity and genitourinary syndrome of menopause. There is a paucity of evidence existing concerning the effectiveness of these devices for both pre- and postmenopausal women with laxity and/or atrophy at the histologic and clinical level. Therefore, the goal of this review is to scrutinize the peer-reviewed data on NVR with RF and laser devices, identify gaps in existing literature, and propose opportunities for further investigation...
September 20, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/29033921/influence-of-oral-and-gut-microbiota-in-the-health-of-menopausal-women
#9
REVIEW
Angélica T Vieira, Paula M Castelo, Daniel A Ribeiro, Caroline M Ferreira
Sex differences in gut microbiota are acknowledged, and evidence suggests that gut microbiota may have a role in higher incidence and/or severity of autoimmune diseases in females. Additionally, it has been suggested that oral, vaginal, and gut microbiota composition can be regulated by estrogen levels. The association of vaginal microbiota with vulvovaginal atrophy at menopause is well described in the literature. However, the relevance of oral and gut microbiota modulation in the immune system during estrogen deficiency and its effect on inflammatory diseases is not well explored...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/28990439/effect-of-foeniculum-vulgare-fennel-on-vaginal-atrophy-in-postmenopausal-women-a-double-blind-randomized-placebo-controlled-trial
#10
Masumeh Ghazanfarpour, Paymaneh Shokrollahi, Talat Khadivzadeh, Nosrat Baharian Sharghi, Khadijeh Mirzaii Najmabadi, Masoudeh Babakhanian, Amir Hossine Jafarian
Objectives This study was conducted to evaluate the effects of orally administered fennel on vaginal atrophy. Materials and methods In this double-blind, randomized, placebo-controlled trial, 60 postmenopausal women living in Mashhad, Iran, were randomly divided into an oral fennel group (n = 30) and a placebo group (n = 30). The Maturation Vaginal Index and maturation values were measured once at baseline and again upon a three-month follow-up. Results The paired t-test showed statistically significant changes in the Maturation Vaginal Index (i...
January 1, 2017: Post Reproductive Health
https://www.readbyqxmd.com/read/28951854/ospemifene-a-novel-option-for-the-treatment-of-vulvovaginal-atrophy
#11
REVIEW
Jae Jun Shin, Seul Ki Kim, Jung Ryeol Lee, Chang Suk Suh
Ospemifene-a third-generation selective estrogen receptor modulator approved by the Food and Drug Administration in 2013-is an oral medication for the treatment of dyspareunia. In postmenopausal women with vulvovaginal atrophy, ospemifene significantly improves the structure and pH levels of the vagina, reducing dyspareunia. It is available as a 60-mg tablet; hence, women who may have had prior difficulty with vaginal administration or on-demand use of nonprescription lubricants and moisturizers would likely prefer this form of treatment...
August 2017: Journal of Menopausal Medicine
https://www.readbyqxmd.com/read/28934376/managing-menopausal-symptoms-and-associated-clinical-issues-in-breast-cancer-survivors
#12
REVIEW
Richard J Santen, Cynthia A Stuenkel, Susan R Davis, JoAnn V Pinkerton, Anne Gompel, Mary Ann Lumsden
Objective: Review evidence to guide management of menopausal signs and symptoms in women after breast cancer and make recommendations accordingly. Evidence: Randomized controlled clinical trials, observational studies, evidence-based guidelines, and expert opinion from professional societies. Background: Symptoms and clinical problems associated with estrogen depletion-sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis-confront the estimated 9...
October 1, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28928886/vulvar-cancer-in-china-epidemiological-features-and-risk-analysis
#13
Xue Xiao, Yi-Bo Meng, Peng Bai, Juan Zou, Ya Zhang, Tri M Bui Nguyen, Jian-Guo Xiao, Xue-Mei Gao, Bang-Fen Wen
Objective: Describe for the first time the clinical, epidemiological features of vulvar cancer in southwest China. Identify risk factors and provide reference for the prevention of vulvar cancer. Method: We retrospectively analyzed 885 patients admitted to the West China Second University Hospital for vulvar diseases between 2006 and 2016. Vulvar cancer patients with previously diagnosed vulvar nonneoplastic epithelial disorders (n=132) were analyzed and compared to those without prior history of vulvar nonneoplastic epithelial disorders (n=219)...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28926514/a-randomized-multicenter-double-blind-study-to-evaluate-the-safety-and-efficacy-of-estradiol-vaginal-cream-0-003-in-postmenopausal-women-with-dyspareunia-as-the-most-bothersome-symptom
#14
Robin Kroll, David F Archer, Yuhua Lin, Vilma Sniukiene, James H Liu
OBJECTIVE: Vulvovaginal atrophy (VVA) is characterized by vaginal changes, dyspareunia, and itching/irritation. Efficacy and safety of a lower-dose estradiol vaginal cream (0.003%) were evaluated in postmenopausal women with VVA-related dyspareunia. METHODS: This was a phase 3, randomized, double-blind, placebo-controlled study. Sexually active postmenopausal women with moderate-severe dyspareunia as the most bothersome symptom, ≤5% vaginal superficial cells, and vaginal pH >5...
September 18, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28894392/fractional-co2-laser-treatment-for-vulvovaginal-atrophy-symptoms-and-vaginal-rejuvenation-in-perimenopausal-women
#15
César Arroyo
BACKGROUND: This study investigated a novel fractional carbon dioxide (CO2) laser for treatment of symptoms associated with vulvovaginal atrophy (VVA) in perimenopausal women. METHODS: The study included 21 perimenopausal women (mean age 45±7 years) treated three times by CO2 laser resurfacing and coagulation of the vaginal canal tissue and mucosal tissue of the introitus. Vaginal health index (VHI) scores were computed by the investigator at baseline and follow-ups...
2017: International Journal of Women's Health
https://www.readbyqxmd.com/read/28887234/vaginal-semisolid-products-technological-performance-considering-physiologic-parameters
#16
Rita Monteiro Machado, Ana Palmeira-de-Oliveira, José Martinez-de-Oliveira, Rita Palmeira-de-Oliveira
Vaginal semisolid products are frequently used to treat vaginal infections and atrophy-related symptoms of menopause. Formulations composition and the methods for their characterization, especially those developed concerning the target epithelia, are key tools to predict in vivo results at early stages of product development. However, recent studies on this subject have been almost exclusively focused on anti-HIV preparations. The aim of this work consists on improving traditional characterization methods by using physiological parameters in order to construct predictive tools to characterize a new ideal vaginal semisolid formulation whatever target it may have...
September 5, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28880384/transabdominal-sonography-to-measure-the-total-vaginal-and-mucosal-thicknesses
#17
Adrian Balica, Katherine Schertz, Daniella Wald-Spielman, Susan Egan, Gloria Bachmann
Transabdominal and transvaginal sonography are used to measure bladder wall and detrusor thickness. Only transvaginal sonography has been used to measure the vaginal wall thickness. We describe the use of transabdominal sonography to measure the total vaginal wall thickness and total vaginal mucosal thickness at the bladder trigone. The mean bladder wall thickness and SD from published data were within the 95% confidence interval of our data. Total vaginal and mucosal thicknesses are reliable measurements, which require specific evaluation in a postmenopausal population...
October 2017: Journal of Clinical Ultrasound: JCU
https://www.readbyqxmd.com/read/28866964/effects-of-soy-isoflavones-on-the-concentration-of-hyaluronic-acid-in-the-vagina-of-type-1-diabetic-rats
#18
A A F Carbonel, P D Azevedo Lima, J J Lim, F Teixeira Borges, G Rodrigues da Silva Sasso, L F Portugal Fuchs, R S Simões, E Chada Baracat, J M Soares, M J Simões
OBJECTIVE: To assess the effects of isoflavones and 17β-estradiol on the vaginal epithelium extracellular matrix and hyaluronic acid (HA) in the diabetic rat model. METHODS: Sixty adult, virgin, female rats underwent ovariectomy, then randomization into six groups of ten animals each: GI, sham ovariectomized control animals; GII, sham ovariectomized control diabetic animals; GIII, control ovariectomized rats receiving propylene glycol vehicle; GIV, control ovariectomized diabetic animals receiving propylene glycol vehicle; GV, diabetic ovariectomized animals treated with soy isoflavones (150 mg/kg by gavage); GVI, ovariectomized diabetic rats treated with estrogen (17β-estradiol, 10 mg/kg, subcutaneously)...
September 2, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28866727/long-term-reliability-of-fractioned-co2-laser-as-a-treatment-for-vulvovaginal-atrophy-vva-symptoms
#19
Annalisa Pieralli, Claudia Bianchi, Manuela Longinotti, Serena Corioni, Noemi Auzzi, Angelamaria Becorpi, Maria Grazia Fallani, Giuseppe Cariti, Felice Petraglia
PURPOSE: The aim of this study was to evaluate long-term effects of the fractional CO2 laser for the treatment of vulvovaginal atrophy (VVA) symptoms. METHODS: Women presenting with VVA symptoms and meeting inclusion criterion were enrolled to fractioned CO2 laser therapy. Patient's satisfaction was measured on five-point Likert scale at 4 weeks and 6, 12, 18, 24 months after treatment by interview and clinical examination for vaginal livability. RESULTS: 184 patients constituted the final study group: 128 women were spontaneous menopause and 56 were oncological menopause...
November 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28844320/-notice-of-expert-for-modality-and-prescriptions-limits-of-local-estrogenotherapy-for-urinairy-inconfinence-in-women
#20
B Tamarelle, K Charvier, L Badet, J-E Terrier, P Grise, G Mellier, F Golfier, A Ruffion
OBJECTIVE: To develop a consensus of experts on the use of local estrogens in female urinary incontinence. MATERIAL AND METHOD: Following a formalized consensus method (DELPHI), a questionnaire was produced and sent to a first round and then to a second round of experts. The questionnaire consisted of proposals for recommendations for the use of local estrogens in the context of female urinary incontinence. The Survey Monkey(®) survey software allowed the questionnaire to be distributed and the answers obtained to be analyzed...
August 24, 2017: Progrès en Urologie
keyword
keyword
19676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"